Michael S. Sagmeister

Dr. Michael S. Sagmeister


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
MSMichael S. Sagmeister
Michael S. Sagmeister
LHLorraine Harper
Lorraine Harper
RHRowan S. Hardy
Rowan S. Hardy
Chronic kidney disease (CKD) describes the long-term condition of impaired kidney function from any cause. CKD is common and associated with a wide array of complications including higher mortality, cardiovascular disease, hypertension, insulin resistance, dyslipidemia, sarcopenia, osteoporosis, aberrant immune function, cognitive impairment, mood disturbances and poor sleep quality. Glucocorticoids are endogenous pleiotropic steroid hormones and their excess produces a pattern of morbidity that possesses considerable overlap with CKD. Circulating levels of cortisol, the major active glucocorticoid in humans, are determined by a complex interplay between several processes. The hypothalamic-pituitary-adrenal axis (HPA) regulates cortisol synthesis and release, 11β-hydroxysteroid dehydrogenase enzymes mediate metabolic interconversion between active and inactive forms, and clearance from the circulation depends on irreversible metabolic inactivation in the liver followed by urinary excretion. Chronic stress, inflammatory states and other aspects of CKD can disturb these processes, enhancing cortisol secretion via the HPA axis and inducing tissue-resident amplification of glucocorticoid signals. Progressive renal impairment can further impact on cortisol metabolism and urinary clearance of cortisol metabolites. Consequently, significant interest exists to precisely understand the dysregulation of cortisol in CKD and its significance for adverse clinical outcomes. In this review, we summarize the latest literature on alterations in endogenous glucocorticoid regulation in adults with CKD and evaluate the available evidence on cortisol as a mechanistic driver of excess mortality and morbidity. The emerging picture is one of subclinical hypercortisolism with blunted diurnal decline of cortisol levels, impaired negative feedback regulation and reduced cortisol clearance. An association between cortisol and adjusted all-cause mortality has been reported in observational studies for patients with end-stage renal failure, but further research is required to assess links between cortisol and clinical outcomes in CKD. We propose recommendations for future research, including therapeutic strategies that aim to reduce complications of CKD by correcting or reversing dysregulation of cortisol.

Verified
Journal Article
Open access
PDF file
JWJustine Webster
Justine Webster
MSMichael S. Sagmeister
Michael S. Sagmeister
CFChloe Fenton
Chloe Fenton
ASAlex P. Seabright
Alex P. Seabright
YLYu-Chiang Lai
Yu-Chiang Lai
RHRowan S Hardy
Rowan S Hardy
Glucocorticoids provide indispensable anti-inflammatory therapies. However, metabolic adverse effects including muscle wasting restrict their use. The enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) modulates peripheral glucocorticoid responses through pre-receptor metabolism. This study investigates how 11β-HSD1 influences skeletal muscle responses to glucocorticoid therapy for chronic inflammation. We assessed human skeletal muscle biopsies from patients with rheumatoid arthritis and osteoarthritis for 11β-HSD1 activity ex vivo. Using the TNF-α-transgenic mouse model (TNF-tg) of chronic inflammation, we examined the effects of corticosterone treatment and 11β-HSD1 global knock-out (11βKO) on skeletal muscle, measuring anti-inflammatory gene expression, muscle weights, fiber size distribution, and catabolic pathways. Muscle 11β-HSD1 activity was elevated in patients with rheumatoid arthritis and correlated with inflammation markers. In murine skeletal muscle, glucocorticoid administration suppressed IL6 expression in TNF-tg mice but not in TNF-tg11βKO mice. TNF-tg mice exhibited reductions in muscle weight and fiber size with glucocorticoid therapy. In contrast, TNF-tg11βKO mice were protected against glucocorticoid-induced muscle atrophy. Glucocorticoid-mediated activation of catabolic mediators (FoxO1, Trim63) was also diminished in TNF-tg11βKO compared to TNF-tg mice. In summary, 11β-HSD1 knock-out prevents muscle atrophy associated with glucocorticoid therapy in a model of chronic inflammation. Targeting 11β-HSD1 may offer a strategy to refine the safety of glucocorticoids.

2 September 2025 in Osteoarthritis and Cartilage
Verified
Journal Article
Open access
SWSusanne Wijesinghe
Susanne Wijesinghe
MMMichael MacLeod
Michael MacLeod
ENEllie Northall
Ellie Northall
CDCaitlin Ditchfield
Caitlin Ditchfield
TNTom Nicholson
Tom Nicholson
SJSimon W Jones
Simon W Jones
To investigate the inflammatory profiles of adipose tissues from patients with osteoarthritis (OA), comparing the joint-associated adipose tissues (infrapatellar fat pad (IFP) and sub-synovial (SSAT)) with subcutaneous adipose tissue (SCAT), and to explore adipose-joint cell crosstalk. RNA sequencing was performed on autologous IFP, SSAT, and SCAT from six patients. The adipose tissue secretome was profiled using targeted proteomics. Primary joint cells (synovial fibroblasts, osteoblasts, and chondrocytes) were treated with adipose-conditioned media for 24 h, followed by RNA sequencing (N=6 per treatment). Key findings were validated using qPCR, ELISA, and recombinant protein treatments. IFP and SSAT exhibited distinct transcriptomic profiles, with 649 and 1263 differentially expressed genes (DEGs), respectively (FDR<0.1). Both IFP and SSAT showed enrichment in inflammation-related pathways, with IFP linked to innate immunity and neuroinflammation, whilst SSAT was associated with metabolism of cholesterol (p<0.05). Proteomic analysis identified 33 elevated biomarkers secreted by IFP and SSAT (p<0.05). Treatment with adipose conditioned media revealed adipose-derived signals modulated joint cell behaviour. Upstream regulator analysis identified common inflammatory and metabolic regulators across adipose conditioned media treated cells, 12 of which were detected in IFP and SSAT secretome. Further validation confirmed that transcriptional signatures identified in joint cells were driven by these shared regulators. Our findings demonstrate that joint adipose tissues contribute to inflammatory and metabolic dysfunction in OA joints. These interactions offer insight into disease pathophysiology and may help identify candidate therapeutic targets, although further in vivo studies are needed to confirm their functional relevance.

10 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TNTom Nicholson
Tom Nicholson
MSMichael S. Sagmeister
Michael S. Sagmeister
SWSusanne Wijesinghe
Susanne Wijesinghe
HFHussein Farah
Hussein Farah
RHRowan S Hardy
Rowan S Hardy
SJSimon W Jones
Simon W Jones
Age-related disorders of the musculoskeletal system including sarcopenia, osteoporosis and arthritis represent some of the most common chronic conditions worldwide, for which there remains a great clinical need to develop safer and more efficacious pharmacological treatments. Collectively, these conditions involve multiple tissues, including skeletal muscle, bone, articular cartilage and the synovium within the joint lining. In this review, we discuss the potential for oligonucleotide therapies to combat the unmet clinical need in musculoskeletal disorders by evaluating the successes of oligonucleotides to modify candidate pathological gene targets and cellular processes in relevant tissues and cells of the musculoskeletal system. Further, we discuss the challenges that remain for the clinical development of oligonucleotides therapies for musculoskeletal disorders and evaluate some of the current approaches to overcome these.

19 October 2018 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
MSMichael S. Sagmeister
Michael S. Sagmeister
MWMax Weiss
Max Weiss
PEPeter Eichhorn
Peter Eichhorn
AHAntje Habicht
Antje Habicht
RHRupert Habersetzer
Rupert Habersetzer
USUlf Schönermarck
Ulf Schönermarck
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis causes end-stage renal failure in up to a third of cases even with treatment. The disease recurs occasionally after kidney transplantation, but new onset of ANCA-associated vasculitis after transplantation is highly unusual. The use of rituximab or plasmapheresis for de novo disease after transplantation has not previously been reported. Routine post-transplant follow-up for a 66-year old asymptomatic woman revealed a rise in creatinine from 1.8 to 2.6 mg/dl and increased proteinuria. She had received a cadaveric kidney transplant 20 months previously for end-stage autosomal dominant polycystic kidney disease. Renal allograft biopsy unexpectedly demonstrated pauci-immune glomerulonephritis with extracapillary proliferation and interstitial inflammation. Concurrent serum tested strongly positive for ANCA specific to proteinase 3 (PR3), but stored pre- and post-transplantation serum samples tested negative. These findings established a diagnosis of de novo ANCA-associated vasculitis in the renal allograft. We started treatment with high-dose corticosteroid and rituximab. Despite this, serum creatinine continued to rise and glomerulonephritis remained active in a repeat biopsy. Escalation of the treatment with seven sessions of plasmapheresis led to a temporary improvement in creatinine. No further features of vasculitis emerged and PR3-ANCA titres declined. However, multiple infections complicated the recovery period and were associated with progressive loss of renal transplant function. Four months after the index presentation, transplant function became insufficient and dialysis was restarted. De novo ANCA-associated vasculitis after renal transplantation is exceptionally rare. It poses a significant risk to graft survival even in the context of intensified immunosuppression. Management relies on clinical evidence from populations with native renal function, yet post-transplant patients may be at increased risk of treatment-related adverse events. Precautions against these risks are crucial in the delivery of care.

1 February 2017 in The Lancet
Verified
Journal Article
Open access
PDF file
DCDimitrios Chanouzas
Dimitrios Chanouzas
MSMichael S. Sagmeister
Michael S. Sagmeister
LDLovesh Dyall
Lovesh Dyall
PNPeter Nightingale
Peter Nightingale
CFCharles Ferro
Charles Ferro
LHLorraine Harper
Lorraine Harper
Background CD4+CD28– T-cell expansion is linked to increased infection and mortality in patients with ANCA-associated vasculitis (AAV), and cardiovascular disease in other inflammatory conditions. We aimed to characterise these cells in AAV, assess their contribution to arterial stiffness, a marker of cardiovascular disease risk, and in a proof-of-concept, open-label, randomised controlled clinical trial determine whether subclinical cytomegalovirus (CMV) reactivation leads to expansion of CD4+CD28– T cells in AAV. Methods Peripheral blood mononuclear cells from 53 patients with AAV and 30 age-matched healthy volunteers (all CMV positive) were stimulated with CMV lysate. Arterial stiffness was measured by pulse wave velocity (Vicorder, Skidmore Medical Ltd, Bristol, UK). 38 CMV-positive AAV patients were computer randomised (1:1) to 6 months' valaciclovir (2 g four times a day) or no additional treatment (19 in each group). Primary outcome was proportion of patients with CMV reactivation at 6 months, assessed by plasma and urine real-time PCR. Secondary outcome was change in proportion of CD4+CD28– T cells from baseline to 6 months. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01633476. Findings CD4+CD28– cells expressed endothelial receptors CX3CR1, CD49d, and CD11b, and cytotoxic molecules perforin and granzymeB, and secreted interferon γ and tumour necrosis factor α after CMV lysate stimulation. The proportion of CD4+CD28– cells was independently associated with increased pulse wave velocity in AAV after controlling for relevant confounders. No CMV reactivation was detected in valaciclovir-treated patients whereas reactivation was detected in controls (4/19 [21·1%], p=0·037). At 6 months there was a significant reduction in both percentage (mean reduction 23%, 95% CI 3–39; p=0·039) and absolute count (27%, 7–42; p=0·013) of CD4+CD28– cells in treated patients with no significant change in controls. CD4+CD28– cell reduction in the treated group persisted 6 months after cessation of treatment. Valaciclovir was well tolerated. Interpretation CD4+CD28– cells are a CMV-specific, cytotoxic, proinflammatory subset that possess endothelial targeting receptors and are independently associated with increased arterial stiffness in inflammatory disease. Blocking subclinical CMV reactivation led to a persistent reduction in CD4+CD28– cells; this finding suggests that CMV subclinical reactivation causes the expansion of this cytotoxic T-cell subset and offers novel therapeutic opportunities in AAV to reduce the risk of infection, cardiovascular disease, and mortality. Funding Wellcome Trust (research training fellowship for DC), Vasculitis UK.